Direct-to-Consumer Marketing

Advertising a prescription medicine to the public is broadly lawful in only a couple of jurisdictions, the United States being the principal one; most regulators prohibit it while allowing disease-awareness campaigns naming a condition but no product. Where it is permitted the format is regulated. A product claim advertisement must present benefit and risk with fair balance and carry the major statement of important risks; a reminder advertisement names the product but makes no claims.

Enforcement is concrete and public. The FDA's promotional office issues untitled and warning letters, most often for overstating efficacy or minimising risk, and publishes them. A 2023 final rule tightened how the major statement of side effects must be presented in broadcast advertising, requiring it to be clear, conspicuous and neutral. For products that are not prescription drugs the Federal Trade Commission requires competent and reliable scientific evidence behind health claims.

Fair balance turns an advertisement into a document with known constraints, which makes its omissions readable. If a piece names an indication it has had to name the risks; if it names neither, it is a reminder or help-seeking format and is telling you less than it appears to. That structure also lets a reader compare the advertisement against the approved label, which bounds what may lawfully be claimed.

The mistake is importing those expectations into channels where none of the rules apply. Compounded preparations, research-labelled substances and supplement-adjacent products are promoted with no fair-balance obligation, no required risk statement and no premarket review of the claim, so their marketing reads as calm and side-effect-free by construction. The absence of a risk paragraph indicates an unregulated channel rather than a gentler product.